Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Anavex Life Sciences (AVXL) Stock Price
Media coverage about Anavex Life Sciences (NASDAQ:AVXL) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Anavex Life Sciences earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.1348374790059 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern’s rankings:
- Anavex Life Sciences’ (AVXL) CEO Christopher Missling on Q3 2018 Results – Earnings Call Transcript (seekingalpha.com)
- Anavex Life Sciences’ (AVXL) Buy Rating Reiterated at Maxim Group (americanbankingnews.com)
- Anavex Life Sciences Corp. to Host Earnings Call (finance.yahoo.com)
- Anavex Life Sciences (AVXL) Announces Quarterly Earnings Results, Beats Expectations By $0.04 EPS (americanbankingnews.com)
- Anavex Life Sciences Reports Fiscal Third Quarter 2018 Financial Results (finance.yahoo.com)
AVXL has been the subject of several recent analyst reports. HC Wainwright initiated coverage on Anavex Life Sciences in a report on Wednesday, May 30th. They issued a “buy” rating and a $10.00 price target for the company. Maxim Group reaffirmed a “buy” rating and set a $7.00 target price (up from $5.00) on shares of Anavex Life Sciences in a report on Thursday, May 31st. Zacks Investment Research raised Anavex Life Sciences from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a report on Wednesday, May 16th. Finally, Noble Financial set a $7.00 target price on Anavex Life Sciences and gave the company a “buy” rating in a report on Wednesday, May 16th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $6.55.
Anavex Life Sciences (NASDAQ:AVXL) last posted its earnings results on Thursday, August 9th. The biotechnology company reported ($0.06) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.04. sell-side analysts forecast that Anavex Life Sciences will post -0.39 EPS for the current fiscal year.
About Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers. The company's lead drug candidates include ANAVEX 2-73, which has completed Phase IIa clinical trials for the treatment of Alzheimer's disease; and in preclinical clinical trials to treat Parkinson's disease, epilepsy, Rett syndrome, Angelman syndrome, multiple sclerosis, and Fragile X syndrome.
Read More: What does relative strength index mean?
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.